Phibro Animal Health Corporation (PAHC) Stock Price & Analysis
Phibro Animal Health Corporation (PAHC) closed at USD 37.98 on Thursday, October 15, 2026, up 0.13% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 37.93; the Oct 15, 2026 session ranged USD 37.83–39.64 on volume of 184,693 shares. Market capitalization is $1.54B, with a 52-week range of USD 28.25–60.08 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PAHC.md
Key facts (PAHC)
- Analysts: Hold (mean 3.00 on a 1–5 scale) (4 analysts), mean target USD 44 (range 35–55).
- Total return with dividends: 1Y -0.3% vs S&P 500 +18.1%; 5Y +97.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.76, revenue estimate $382M.
Analysts (PAHC)
Consensus Hold (mean 3.00 on a 1–5 scale), 4 analysts; mean target USD 44 (low 35, high 55).
Total return (dividends reinvested) (PAHC)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -0.3% | +97.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -0.3% | +14.5% |
| Volatility (annualized) | 55.6% | 46.0% |
| Max drawdown | -52.1% (Apr 2026→Jun 2026) | -54.9% (Nov 2021→Nov 2023) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 37.98 |
|---|---|
| Change | ▲ 0.13% (up) |
| Previous Close | USD 37.93 |
| Open | USD 38.19 |
| Day Range | USD 37.83 – 39.64 |
| 52-Week Range | USD 28.25 – 60.08 |
| Volume | 184,693 shares |
| Market Cap | $1.54B |
| Exchange | NGM |
Technical Analysis (PAHC)
Nexqual's technical model rates PAHC "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.47 (neutral) |
| vs SMA50 | Above (USD 36.04) |
| MACD | 0.56 (positive) |
Analyst Ratings (PAHC)
Wall Street analysts rate PAHC "Hold" based on 4 analysts, with a mean price target of USD 44 (range USD 35–55), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 44 |
| High Target | USD 55 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 1 / 2 / 1 |
Earnings (PAHC)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.76 |
| Revenue Estimate | $381.89M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.85 vs est 0.73 ▲ beat |
| 2026-03-31 | USD 0.76 vs est 0.71 ▲ beat |
| 2025-12-31 | USD 0.87 vs est 0.67 ▲ beat |
| 2025-09-30 | USD 0.73 vs est 0.6 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (PAHC)
| Total Revenue | $1.52B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.80% |
| Gross Margin | +33.33% |
| Operating Margin | +10.64% |
| Profit Margin | +6.57% |
| ROE | +29.72% |
| Debt / Equity | 2.06 |
| Current Ratio | 2.96 |
| Total Cash | $83.98M |
| Total Debt | $795.65M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (PAHC)
Nexqual rates Phibro Animal Health Corporation's overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 33%, operating 11% |
| Balance Sheet | Weak — $84M cash vs $796M debt |
| Cash Flow | Solid — Operating cash flow $69M (TTM) |
| Efficiency | Strong — ROE 30%, ROA 8.5% |
Ownership (PAHC)
| Insider Ownership | +0.88% |
|---|---|
| Institutional Ownership | +103.97% |
| Shares Outstanding | 21.11M |
| Float | 20.91M |
| Short % of Float | +7.01% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (PAHC)
Phibro Animal Health Corporation is led by Daniel M. Bendheim (age 53), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO, President & Director | Daniel M. Bendheim (age 53) |
|---|---|
| Executive Chairman | Jack Clifford Bendheim (age 78) |
| Chief Financial Officer | Glenn C. David (age 53) |
| Chief Operating Officer | Larry L. Miller (age 61) |
| Executive VP of Talent, Technology and Business Development & Director | Jonathan Bendheim (age 49) |
Major Backers & Investors (PAHC)
Notable institutional backers of Phibro Animal Health Corporation include FMR, LLC, Fidelity, Lord, Abbett & Co. LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.97% |
| Fidelity | 7.04% |
| Lord, Abbett & Co. LLC | 4.73% |
| Millennium Management | 4.44% |
| Renaissance Technologies | 2.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.88% |
| Vanguard Group | 11.06% |
| State Street | 4.92% |
| Geode Capital | 3.11% |
| Dimensional Fund Advisors | 2.52% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt